N-(3,4-dihydroxyhydrocinnamoyl)dopamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: N-(3,4-dihydroxyhydrocinnamoyl)dopamine
• 英文别名: 3-(3,4-dihydroxyphenyl)-N-[2-(3,4-dihydroxyphenyl)ethyl]propanamide
• 化学式: C₁₇H₁₉NO₅
• 分子量: 317.342
• InChiKey: JSRZDPROOJRCNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  110
• 氢给体数：
  5
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,4-二羟基苯基丙酸 在 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N-(3,4-dihydroxyhydrocinnamoyl)dopamine
  参考文献：
  名称：

  Hydroxylated Aromatic Inhibitors of HIV-1 Integrase

  摘要：

  Efficient replication of HIV-1 requires integration of a DNA copy of the viral genome into a chromosome of the host cell. Integration is catalyzed by the viral integrase, and we have previously reported that phenolic moieties in compounds such as flavones, caffeic acid phenethyl ester (CAFE, 2), and curcumin confer inhibitory activity against HIV-1 integrase. We now extend these findings by performing a comprehensive structure-activity relationship using CAPE analogues. Approximately 30 compounds have been prepared as HIV integrase inhibitors based on the structural lead provided by CAPE, which has previously been shown to exhibit an IC50 value of 7 mu M in our integration assay. These analogues were designed to examine specific features of the parent CAFE structure which may be important for activity. Among the features examined for their effects on inhibitory potency were ring substitution, side chain length and composition, and phenyl ring conformational orientation. In an assay which measured the combined effect of two sequential steps, dinucleotide cleavage and strand transfer, several analogues have IC50 values for 3'-processing and strand transfer lower than those of CAFE. Inhibition of strand transfer was assayed using both blunt-ended and ''precleaved'' DNA substrates. Disintegration using an integrase mutant lacking the N-terminal zinc finger and C-terminal DNA-binding domains was also inhibited by these analogues, suggesting that the binding site for these compounds resides in the central catalytic core. Several CAFE analogues were also tested for selective activity against transformed cells. Taken together, these results suggest that the development of novel antiviral agents for the treatment of acquired immune deficiency syndrome can be based upon inhibition of HIV-1 integrase.

  DOI：

  10.1021/jm00021a006

文献信息

• [EN] SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES<br/>[FR] N-BENZAMIDES D'ARYLE SUBSTITUÉS ET COMPOSÉS LIÉS POUR TRAITEMENT DES MALADIES AMYLOÏDES ET DES SYNUCLÉINOPATHIES
  申请人：PROTEOTECH INC

  公开号：WO2005113489A1

  公开（公告）日：2005-12-01

  Substituted diaryl compounds of the Formulae (I, II, III), where the variables are as defined in the claims, and their pharmaceutically acceptable derivatives, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aß amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided.

  根据权利要求中定义的变量，提供了公式（I，II，III）的取代二芳基化合物及其药学上可接受的衍生物，它们的合成，含有它们的药物组合物，以及它们在治疗淀粉样疾病中的用途，包括阿尔茨海默病中观察到的Aß淀粉样病变，如2型糖尿病中观察到的IAPP淀粉样病变，以及在帕金森病中观察到的α-突触核病变，并提供了用于制造这种治疗药物的方法。
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE<br/>[FR] COMPOSES, COMPOSITIONS ET PROCEDES DE TRAITEMENT DE MALADIES AMYLOIDES ET DE SYNUCLEINOPATHIES, NOTAMMENT DE LA MALADIE D'ALZHEIMER, DU DIABETE DE TYPE 2 ET DE LA MALADIE DE PARKINSON
  申请人：PROTEOTECH INC

  公开号：WO2003101927A1

  公开（公告）日：2003-12-11

  Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aß amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinophathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

  双-和三-二羟基芳基化合物及其亚甲二氧基类似物和药用可接受酯，它们的合成，含有它们的药物组合物，以及它们在治疗淀粉样疾病，特别是Aß淀粉样病变，如阿尔茨海默病中观察到的，IAPP淀粉样病变，如2型糖尿病中观察到的，以及α-突触核病，如帕金森病中观察到的，以及用于制造用于此类治疗的药物。
• Identification and Quantification of Potential Anti-inflammatory Hydroxycinnamic Acid Amides from Wolfberry
  作者：Siyu Wang、Joon Hyuk Suh、Xi Zheng、Yu Wang、Chi-Tang Ho

  DOI：10.1021/acs.jafc.6b05136

  日期：2017.1.18

  their active components. We synthesized a set of hydroxycinnamic acid amide (HCCA) compounds, including trans-caffeic acid, trans-ferulic acid, and 3,4-dihydroxyhydrocinnamic acid, with extended phenolic amine components as standards to identify and quantify the corresponding compounds from wolfberry and to investigate anti-inflammatory properties of these compounds using in vitro model. With optimized

  枸杞子或枸杞的果枸杞，具有促进健康的特性，导致其有效成分的深入研究。我们合成了一组羟基肉桂酸酰胺（HCCA）化合物，包括反式咖啡酸，反式-阿魏酸和3,4-二羟基氢肉桂酸（含扩展的酚胺成分）作为标准品，用于鉴定和定量枸杞中的相应化合物，并使用体外模型研究这些化合物的抗炎特性。通过优化的LC-MS / MS和NMR分析，从水果中鉴定出9种酰胺化合物。这些化合物中有7种是首次在该植物中鉴定出来的。具有酪胺部分的酰胺化合物最丰富。体外研究表明，5个HCCA化合物显示出对NO产生由脂多糖与IC inuded抑制作用50小于15.08μM（反式- ñ -feruloyl多巴胺）。这些发现表明，枸杞具有抗炎特性。
• Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and parkinson's disease
  申请人：——

  公开号：US20040127555A1

  公开（公告）日：2004-07-01

  Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A&bgr; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

  双和三羟基芳基化合物及其亚甲二氧基类似物和药学上可接受的酯，其合成方法，包含它们的药物组成物，以及它们在治疗淀粉样疾病中的应用，特别是Aβ淀粉样蛋白病，如阿尔茨海默病，IAPP淀粉样蛋白病，如2型糖尿病中观察到的，以及突触核蛋白病，如帕金森病中观察到的，以及用于制造此类治疗药物。
• Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
  申请人：Snow D. Alan

  公开号：US20060199838A1

  公开（公告）日：2006-09-07

  Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable derivatives, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided.

  本发明提供了取代的n-芳基苯甲酰胺，相关化合物及其药学上可接受的衍生物，它们的合成方法，含有它们的制药组合物，以及它们在治疗淀粉样疾病中的应用，包括Aβ淀粉样蛋白病，如阿尔茨海默病中观察到的IAPP淀粉样蛋白病，如2型糖尿病中观察到的以及突触核蛋白病，如帕金森病中观察到的，以及制造用于这种治疗的药物。